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A series of quinazolinone derived Schiff base derivatives 7–28 were synthesized and characterized as
novel antioxidants and anti-inﬂammatory agents. The in vitro antioxidant activities of these compounds
were evaluated and compared with commercial antioxidants ascorbic acid (AA), gallic acid (GA), buty-
latedhydroxytoluene (BHT), butylatedhydroxyanisole (BHA) employing 1,1-diphenyl-2-picryl-hydrazyl
(DPPH) assay, 2,2-azinobis-(3-ethylbenzothiazoline-6-sufonic acid) (ABTS) assay and N,N-dimethyl-p-
phenylenediamine dihydrochloride (DMPD) assay. The results revealed that IC50 of 17, 18, 23, 24, 25,
27 and 28 were lower than the IC50 of standards in all the three performed antioxidant assays indicating
good activities of these compounds. In addition, in vitro anti-inﬂammatory activity of the synthesized
compounds were evaluated and the results demonstrate that the compounds 9–12 exhibited excellent
anti-inﬂammatory activity. Preliminary structure–activity relationship revealed that the compounds
17, 18, 23, 24, 25, 27 and 28 with electron donating moiety (OH, OCH3) were found to be excellent anti-
oxidants and compounds 9, 10, 11 and 12 with electron withdrawing moiety (Cl, NO2) were found to be
excellent anti-inﬂammatory agents.
 2015 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).The Schiff’s base family is composed of natural products with
critical pharmacophores.1 It can be used as ideal lead structures
to develop agrochemicals and medicines, including fungicide,2
bactericide,3 antivirals,4 antioxidants,5 antiproliferative6 and anti-
microbial drug.7 Various natural alkaloids with critical pharmaco-
phores contain quinazolinone groups. For example, febrifugine,
isofebrifugine, thiabutazide, ()-benzomalvin A, 2-(4-hydroxybu-
tyl) quinazolin-4-one, and luotonin F were found in the plants, ani-
mals, and microorganisms.8,9 Moreover, The quinazolinone nucleus
and its derivatives have been extensively studied because of their
wide range of pharmacological activities. As medicines, many of
them display antitubercular,10 anti-inﬂammatory,11 anticonvul-
sant,12 antidepressant,13 antiulcer14 and analgesic15 activities.
Antioxidants play a vital role in the defense mechanism against
oxidative damage induced by free radicals and reactive oxygen
species (ROS). Balanced reactive oxygen species generation and
detoxiﬁcation in a normal cellular metabolism is important to keep
the mammalian cells in healthy condition. When a cell fails to
detoxify the excessive ROS generated as a result of damaging spe-
cies or low level of antioxidants, they enter into a state of oxidative
stress and is damaged.16 High levels of ROS can cause damage to
cell structure, nucleic acids, membrane lipids and proteins.17 Theyalso damage purine and pyrimidine bases of DNA molecule, thus
leading to mutation.18 Oxidative stress on a cell due to high
concentration of ROS can leads to a variety of disorders including
cancer, neurodegenerative disorder, atherosclerosis and aging.19
Many studies have suggested that antioxidants or other com-
pounds that can neutralize free radicals may be of pivotal interest
in the prevention of vascular diseases and some forms of cancer.20
The attachment of hydroxyl groups on the aromatic ring makes
hydroxyl-substituted Schiff’s bases the effective antioxidants, and
potential drugs to prevent disease related to free radical damage.
Recently, Liu and co-workers have reported the protective effects
of hydroxyl-substituted Schiff’s bases against free radical-induced
peroxidation of triolein in micelles, haemolysis of human red cells,
and oxidation of DNA.21,22 Some of the recently reported23–27
structures of the biologically active Schiff’s bases are shown in
Figure 1. The length of alkyl chain play an important role in
deciding biological activities. The antioxidant activity of p-alkyl-
aminophenols enhanced by elongation of alkyl chain.28 Similarly
anti-inﬂammatory activity of 2-amino-alcohols was enhanced by
increasing the alkyl chain length.29
Non-steroidal anti-inﬂammatory drugs (NSAIDs) are the most
commonly prescribed medications in the world. They are used for
the treatment of pain, fever and inﬂammation, particularly
arthritis.30 Rheumatic diseases are the most prevalent causes of
disability in European countries and non-steroidal anti-inﬂammatory
NN
O
N
OR
N
O
H
N
O
N
H
N R
N
N
O
NH
N R2
R1
OMe
N
H
O
N R
MeO
HO
MeO
N NH
R
Figure 1. Structures of the biologically active Schiff’s bases.
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use may cause several serious adverse effects, the most important
one being gastric injury and renal complications. Gastro-intestinal
(GI) damage from NSAIDs is generally attributed to two factors:
local irritation by the direct contact of the free carboxylic acid
(COOH) moiety of NSAIDs with GI mucosal cells (topical effect)
and decreased tissue prostaglandin production in tissues.31
Based on the above facts and in continuation of our drug devel-
opment program,32–34 the present work involves the synthesis of a
new series of quinazolinone derived Schiff’s base derivatives as
potential anti-inﬂammatory and antioxidants.
Synthesis of the desired compounds were achieved according to
the steps illustrated in Scheme 1. 3-(4-Oxo-3,4-dihydroquinozolin-
2-yl)propanoic acid (QZN 1) and 4-(4-oxo-3,4-dihydroquinozolin-
2-yl)butanoic acid (QZN 2)35–37 were methylated using trimethyl-
silylchloride (TMS-Cl) and methanol at room temperature,41 which
upon reaction with excess of hydrazine hydrate afforded the corre-
sponding quinazolinone hydrazides (5 and 6).42 The Schiff’s bases
(7–28) were obtained by reacting 5 and 6 with different aromatic
aldehydes in presence of catalytic amount of glacial acetic acid.43
All the derivatives were obtained in high yield and the methods
employed are very simple. The structures of all the newly synthe-
sized compounds including intermediates were conﬁrmed by IR,
1H NMR, 13C NMR and mass spectral analysis (Supplementary
material). The formation of methyl esters (3 and 4) were conﬁrmed
by the appearance of a singlet at 3.68 d for OCH3 and absence of
COOH proton peak at 12.25 d in 1H NMR spectrum. In IR spectra,
bands at 3310 and 3217 cm1 for NH2–NH groups indicates the
conversion of methyl esters into hydrazides. The formation of
Schiff’s bases were conﬁrmed by the presence of absorption at
1612–1630 cm1 for imines, i.e., AN@CHA in IR spectra. The pres-
ence of all requisite peaks and absence of extraneous peaks in 1H
NMR and 13C NMR conﬁrms the structures.
In vitro antioxidant activities of all the synthesized compounds
including intermediates were evaluated by (i) 1,1-diphenyl-2-pic-
ryl-hydrazyl (DPPH) assay which is a rapid and convenient
technique for screening the antioxidant activities of the
antioxidants, (ii) 2,2-azinobis-3-ethylbenzothiazoline-6-sufonic
acid (ABTS) cation radical assay which is a conventional and excel-
lent model for assessing the antioxidant activities of hydrogen
donating and chain breaking antioxidants.38 and (iii) N,N-N
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Scheme 1. Synthesis of ﬁnal compounds 7–28. Reagents and conditions: (i) TMS-Cl, Medimethyl-p-phenylenediamine dihydrochloride (DMPD) cation
radical assay which is similar to the DPPH radical scavenging assay.
The values of IC50, the effective concentration at which 50% of the
radicals were scavenged, were calculated to evaluate the antioxi-
dant activities. A lower IC50 value indicated greater antioxidant
activity. IC50 values of lower than 10 mg/mL usually implied
effective activities in antioxidant properties.39 The IC50 of
butylatedhydroxytoluene (BHT), butylatedhydroxyanisole (BHA),
ascorbic acid (AA) and gallic acid (GA) was also determined for
comparison. The results were shown in Table 1.
Most of the synthesized compounds showed potent antioxidant
activities. Compounds 17, 18, 22, 23, 24, 25, 26, 27 and 28 showed
excellent radical scavenging activities with IC50 values 113, 95, 97,
104, 88, 85, 106, 81 and 78 lM/mL, respectively, in DPPH assay
much better than the standard BHT (IC50 = 114 lM/mL). In ABTS+
radical scavenging assay, the compounds 17, 18, 23, 24, 25, 27
and 28 showed potent antioxidant activity with IC50 values 40,
50, 40, 50, 55, 35 and 40 lM/mL, respectively, which is much better
than the commercial standards BHA (IC50 = 55 lM/mL), AA
(IC50 = 65 lM/mL) and GA (IC50 = 60 lM/mL). The compounds 17,
18, 23, 24, 25, 27and 28 also exhibited striking antioxidant activity
with IC50 values 105, 75, 50, 80, 80, 45 and 45 lM/mL, respectively,
which is better than the standards BHA (IC50 = 155 lM/mL), AA
(IC50 = 140 lM/mL) and GA (IC50 = 100 lM/mL) in DMPD assay. In
all the three assays performed, the compounds 17, 18, 23, 24, 25,
27 and 28 showed excellent antioxidant activities with IC50 values
much lower than the standards. The IC50 values of these com-
pounds 17, 18, 23, 24, 25, 26, 27 and 28 were found to be in lg/
mL level and much lower than 10 mg/mL demonstrating greater
antioxidant activities of these compounds in all the three assays.
On the basis of the above observation, compounds having –OH
(phenolic) and –OCH3 (anisole) groups in the phenyl ring (17, 18,
23, 24, 25, 27 and 28) were found to be the most potent antioxi-
dants. The compounds with electron withdrawing Cl and NO2 sub-
stituents (9–12) showed least antioxidants activity.
All the synthesized compounds were also evaluated for their
in vitro anti-inﬂammatory activity using known literature proce-
dure in human erythrocytes.40 A substantial number of compounds
have been identiﬁed exhibiting excellent to moderate inhibitory
activity compared to standard drug aspirin. IC50 was determined
for the compounds showing more than 50% inhibition concentra-
tion (Table 1). The compounds 9, 10, 11 and 12 showed excellent
activity with IC50 values 84, 67, 54 and 52 lM/mL, respectively,
much better than the standard aspirin (IC50 = 166 lM/mL). Other
compounds 17, 18, 23, 24, 27 and 28 showed moderate activity.
It is evident from the results that the compounds bearing electron
withdrawing groups Cl and NO2 (9–12) are better anti-inﬂamma-
tory agents.
In conclusion, we have designed and synthesized a series of qui-
nazolinone derived Schiff’s bases with different groups in benzene
ring. Of all the compounds synthesized, compounds 17, 18, 23, 24,
25, 27 and 28 with OH and OCH3 groups in benzene ring (electron
donating) exhibited stronger radical scavenging activities than
BHT, BHA, AA and GA in all the three assays performed. Com-
pounds 9, 10, 11 and 12 with Cl and NO2 in benzene ring (electron
withdrawing) demonstrated better anti-inﬂammatory activityN
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Table 1
Biological activities of the synthesized quinazolinone Schiff’s base derivatives
Entry Antioxidant activitya Anti-inﬂammatory activitya IC50 (lM/mL)
DPPH IC50 (lM/mL) ABTS IC50 (lM/mL) DMPD IC50 (lM/mL)
1 1100 ± 4.49 — — —
2 1250 ± 2.56 — — —
3 862 ± 3.46 — — 1163 ± 4.89
4 772 ± 6.95 280 ± 1.73 — 975 ± 2.16
5 — — — —
6 — — — —
7 734 ± 2.88 265 ± 2.08 — —
8 568 ± 2.94 240 ± 2.18 — —
9 381 ± 3.69 185 ± 2.08 — 84 ± 1.44
10 353 ± 3.10 — — 67 ± 1.24
11 328 ± 2.88 220 ± 1.73 — 54 ± 1.88
12 316 ± 1.73 270 ± 3.36 — 52 ± 0.81
13 238 ± 2.15 105 ± 2.08 300 ± 2.44 —
14 214 ± 2.44 170 ± 1.73 — —
15 214 ± 2.94 75 ± 2.94 — —
16 247 ± 1.63 180 ± 1.24 280 ± 3.62 —
17 113 ± 1.28 40 ± 1.69 105 ± 2.15 255 ± 3.17
18 95 ± 1.63 50 ± 1.20 75 ± 2.15 300 ± 2.17
19 204 ± 2.74 95 ± 1.24 290 ± 2.94 —
20 236 ± 2.08 115 ± 1.28 280 ± 3.87 —
21 126 ± 1.73 105 ± 2.88 275 ± 2.64 530 ± 4.28
22 97 ± 1.69 135 ± 2.16 225 ± 2.05 524 ± 2.87
23 104 ± 1.41 40 ± 2.63 50 ± 1.73 261 ± 4.54
24 88 ± 1.24 50 ± 0.40 80 ± 1.63 277 ± 2.94
25 85 ± 1.28 55 ± 1.77 80 ± 2.05 682 ± 3.10
26 106 ± 2.88 60 ± 1.67 85 ± 2.08 613 ± 3.61
27 81 ± 1.69 35 ± 0.40 45 ± 1.41 203 ± 2.88
28 78 ± 1.20 40 ± 0.81 45 ± 1.69 183 ± 2.17
BHT 114 ± 1.24 — — —
BHA — 55 ± 0.20 155 ± 2.16 —
AA — 65 ± 0.86 140 ± 1.69 —
GA — 60 ± 1.63 100 ± 1.24 —
Aspirin — — — 166 ± 1.24
Bold values are represented as standard drugs.
Standards: BHT = butylatedhydroxytoluene; BHA = butylatedhydroxyanisole; AA = ascorbic acid; GA = gallic acid.
a Values are mean of three determinations, the ranges of which are <5% of the mean in all cases.
Table 2
Chemical structure and physical data of new Schiff’s bases 7–28
Entry R Structure Yield (mg) % age yield Mp (C)
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Table 2 (continued)
Entry R Structure Yield (mg) % age yield Mp (C)
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Table 2 (continued)
Entry R Structure Yield (mg) % age yield Mp (C)
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and the toxicity studies of these compounds are in progress.Acknowledgments
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